AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 34 |
Market Cap | 1.69B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.83 |
PE Ratio (ttm) | -41.85 |
Forward PE | n/a |
Analyst | Buy |
Ask | 39 |
Volume | 490,208 |
Avg. Volume (20D) | 525,252 |
Open | 34.65 |
Previous Close | 34.39 |
Day's Range | 33.87 - 36.15 |
52-Week Range | 18.94 - 39.05 |
Beta | undefined |
About ATRC
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform tem...
Analyst Forecast
According to 8 analyst ratings, the average rating for ATRC stock is "Buy." The 12-month stock price forecast is $40, which is an increase of 15.16% from the latest price.
Next Earnings Release
Analysts project revenue of $119.85M, reflecting a 12.49% YoY growth and earnings per share of -0.15, making a -28.57% decrease YoY.